Current partner codePEPTIDESDE
NCT07057310·Phase 4·INTERVENTIONAL

Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women

Status

Enrolling by invitation

Phase

Phase 4

Enrollment

30

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

In postmenopausal women, obesity increases the risk of physical function decline, premature aging, and vascular dysfunction. Semaglutide and tirzepatide are potent obesity medications. The goal is to determine the effect of weight loss induced by the new generation of GLP-1 receptor agonists on physical function, aging biomarkers, and vascular function in postmenopausal women with obesity.

Interventions

Treatment arms and agents.

DRUG

semaglutide or tirzepatide

Semaglutide and tirzepatide will be dosed as per prescription labels

BEHAVIORAL

Lifestyle modification intervention

All participants will be recommended the following: 1) low-calorie diet based on their predicted by Harris Benedict resting energy expenditure minus 500 kcal per day; 2) physical activity: a goal of 10,000 steps or more per day; 3) exercise: a goal of 150 minutes or more of moderate-intensity aerobic activity (cardiovascular exercise) per week; 4) limited consumption of liquid calories (i.e. sodas, juices, alcohol, etc.).

Timeline

From registration to results.

  1. First posted

    Jul 9, 2025

  2. Study start

    May 1, 2025

  3. Primary completion

    Dec 31, 2026

  4. Study completion

    Mar 31, 2027

  5. Results posted

    Not reported

  6. Registry updated

    Jul 20, 2026

Outcomes

What the study measures.

Primary outcomes

Physical Function Measure: Short Physical Performance Battery (SPPB) score.

Time frame · 24 weeks

The SPPB is a standardized test that evaluates lower extremity function using three components: balance tests (standing in various positions), gait speed (walking a short distance), and chair stand (repeated standing from a seated position). Each component is scored from 0 to 4; the total score ranges from 0 to 12. Higher scores represent better physical function.

Physical Function Measure: Modified Clinical Test of Sensory Interaction in Balance (mCTSIB) performed on the Rehabilitation Artificial Physical Intelligence Database (RAPID) foot pressure mat

Time frame · 24 weeks

The mCTSIB assesses balance under four sensory conditions: eyes open/closed on firm and foam surfaces. Testing is performed while standing on the RAPID foot pressure mat, which captures center of pressure and postural sway data. The primary measure is average sway area of the four sensory conditions. The sway area is the area which is required to correct equilibrium, representing the total area covered by postural sway, measured in square centimeters (cm²).

Physical Function Measure: Standing Chest Throw Test with a 2-kg Weighted Ball using Motion Sensor Technology (MST)

Time frame · 24 weeks

This test evaluates upper body muscular power. Participants perform a two-handed chest throw of a 2-kg medicine ball from a standing position. The MST is used to record throw distance, velocity, and related performance metrics. The primary measure is Peak Power Score (W).

Physical Function Measure: Chair-to-Stand Tests using Motion Sensor Technology (MST)

Time frame · 24 weeks

This test assesses lower body strength and function. Participants are instructed to stand up from a chair and sit back down five times without using their arms. The MST measures movement dynamics. The primary measure is peak power score (W).

Physical Function Measure: Six-Minute Walk Test (6MWT)

Time frame · 24 weeks

The 6MWT is a standardized submaximal exercise test used to assess functional aerobic capacity. Participants are instructed to walk as far as possible in six minutes along a flat, straight course. The total distance walked is recorded in feet. Longer walking distances indicate better aerobic capacity and endurance.

Physical Function Measure: Hand Grip Strength using a Hydraulic Hand Dynamometer

Time frame · 24 weeks

Participants are instructed to squeeze the dynamometer with maximum effort, measured in kilograms. The highest value from multiple trials is recorded.

Physical Function Measure: Short Form-12 (SF-12) Health Survey

Time frame · 24 weeks

The SF-12 is a standardized, self-administered questionnaire designed to assess overall health-related quality of life. It includes 12 items that measure physical and mental health components, generating Physical Component Summary (PCS) and Mental Component Summary (MCS) scores. Scores are standardized on a scale where higher values indicate better health status. Both PCS and MCS scores typically range from 0 to 100, with 0 indicating the poorest health and 100 indicating the best possible health status.

Physical Function Measure: Patient-Reported Outcomes Measurement Information System (PROMIS) - Fatigue and Physical Function Domains

Time frame · 24 weeks

The PROMIS is a standardized set of self-reported questionnaires designed to measure health domains. This study includes the fatigue and physical function domains, which assess the participant's perceived level of tiredness and ability to perform daily physical activities. Responses generate standardized T-scores, calibrated to the general population. Higher fatigue T-scores indicate greater fatigue severity.

Secondary outcomes

Not reported in the indexed record.

Eligibility

Who can take part.

Minimum age
46 Years
Maximum age
60 Years
Sex
FEMALE
Healthy volunteers
No

Inclusion Criteria: * Postmenopausal women (with menopause defined as the cessation of menstrual periods for at least 12 months or history of bilateral oophorecomy) * Age 46-60 years old * BMI ≥ 30 kg/m2. Exclusion Criteria: * Past or current use of menopausal hormone therapy * Early or premature menopause * History of chemically induced menopause * Impaired renal function (GFR ≤29) * Thyroid-stimulating hormone ≥7 with low free T4 * Diabetes * Cardiovascular disease * Elevated blood pressure (\>170/\>95) * Uncontrolled co-morbidities including inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignant, or psychiatric disease * \>5% change in weight during the 3 months prior to screening * Other anti-obesity medication use within the past 3 months * History of bariatric surgery * History of malignant neoplasms within the past 5 years prior to screening * Current use of supplements known to affect weight * Personal or family history of medullary thyroid cancer. * Wheelchair bound * Vision loss

Study locations

1 registered sites.

United States. Showing up to 24 locations stored in the fast local snapshot.

Mayo Clinic in Florida

Jacksonville, Florida, United States

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Tirzepatide.